Basilea Asahi Kasei Cresemba Pediatric Japan Study
Analysis based on 6 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026
The news is a modest positive for Basilea as it expands the potential pediatric label for its largest product, Cresemba, in Japan, though the financial effect is limited until approval and launch. Market reaction was muted, with Basilea shares slightly lower on the day despite touching a 52-week intraday high.
Basilea Pharmaceutica announced that its Japanese partner Asahi Kasei started a Phase 2 clinical study of the antifungal Cresemba (isavuconazole) in Japan for pediatric patients at risk of deep mycoses. The multicenter, open-label, non-controlled study will assess the safety and pharmacokinetics of Cresemba in children. Cresemba is already approved for pediatric use in the United States, Canada, Europe and China, but in Japan it is currently approved only for adults with severe fungal infections. Basilea noted that global in-market sales of Cresemba reached USD 782 million in the twelve months from April 2025 to March 2026, up 27 percent year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide. Basilea also said its Phase 3 program for antifungal Fosmanogepix remains on track for a 2028 data readout and regulatory submission, and that it is preparing Phase 3 development of antibiotic ceftibuten-ledaborbactam while advancing earlier-stage programs. As of June 30, 2026, Basilea held cash, cash equivalents and restricted cash of CHF 175.98 million. Basilea shares reached a 52-week high of CHF 68.00 in intraday trading on Monday and were trading at CHF 66.40, down 0.45 percent on the SIX Swiss Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard